Overview

Non-Alcoholic Steatohepatitis (Nash) Therapeutics And Diagnostics Market is poised to value at a CAGR of over 26% during the forecast period 2021 to 2028.

NASH (nonalcoholic steatohepatitis) develops in patients who do not consume alcohol or who consume alcohol in small amounts. Non-alcoholic steatohepatitis (NASH) is a condition that occurs in the liver without obvious signs or symptoms. Among the major features of NASH is the buildup of fat in the liver, along with inflammation. The fat buildup eventually damages the liver and scars it in this condition, which might result in the formation of cirrhosis. This disease is often hard to diagnose because the symptoms are often hidden. The FDA has not approved a drug to treat NASH at the present time. First-line agents for NASH management are vitamin E & pioglitazone. Lifestyle changes are the primary approach until lifestyle changes are implemented. Growing prevalence of diabetes & obesity in developing regions, as well as higher awareness of NASH, are expected to drive the market during the forecast period.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Non-Alcoholic Steatohepatitis (Nash) Therapeutics And Diagnostics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Non-Alcoholic Steatohepatitis (Nash) Therapeutics And Diagnostics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Non-Alcoholic Steatohepatitis (Nash) Therapeutics And Diagnostics Market:
• Abbvie Inc. (Allergan PLC.)
• Novartis AG
• Quest Diagnostics
• Exalenz Bioscience Ltd.
• Intercept Pharmaceuticals Inc.
• Gilead Sciences Inc.
• Genfit SA
• Novo Nordisk A/S
• Zydus Cadila
• Merck & Co.
• OWL Metabolomics
(Note: The list of the major players will be updated with the latest market scenario and trends)

Non-Alcoholic Steatohepatitis (Nash) Therapeutics And Diagnostics Market Segmentation:          
By Product
• Therapeutics
• Diagnostics
  o Imaging Techniques
  o Diagnostic Tests
  o Biopsy

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Non-Alcoholic Steatohepatitis (Nash) Therapeutics And Diagnostics Market By Product and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Non-Alcoholic Steatohepatitis (Nash) Therapeutics And Diagnostics Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Non-Alcoholic Steatohepatitis (Nash) Therapeutics And Diagnostics Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Non-Alcoholic Steatohepatitis (Nash) Therapeutics And Diagnostics Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Non-Alcoholic Steatohepatitis (Nash) Therapeutics And Diagnostics Market, By Product Historical Analysis and Forecast 2021-2028 (USD Million)  
   7.1. Therapeutics
   7.2. Diagnostics
        7.2.1. Imaging Techniques
        7.2.2. Diagnostic Tests
        7.2.3. Biopsy

8. North America Non-Alcoholic Steatohepatitis (Nash) Therapeutics And Diagnostics Market Analysis 2016-2020 and Forecast 2021-2028 (USD Million)
   8.1. Introduction
   8.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
        8.2.1. U.S.A
        8.2.2. Canada
        8.2.3. Mexico
   8.3. Market Size (USD Million) Forecast for North America 2021-2028

9. Latin America Non-Alcoholic Steatohepatitis (Nash) Therapeutics And Diagnostics Market Analysis 2016-2020 and Forecast 2021-2028 (USD Million)
    9.1. Introduction
    9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         9.2.1. Brazil
         9.2.2. Venezuela
         9.2.3. Argentina
         9.2.4. Rest of Latin America
    9.3. Market Size (USD Million) Forecast for Latin America 2021-2028

10. Europe Non-Alcoholic Steatohepatitis (Nash) Therapeutics And Diagnostics Market Analysis 2016-2020 and Forecast 2021-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. Germany
          10.2.2. U.K         
          10.2.3. France
          10.2.4. Italy
          10.2.5. Spain
          10.2.6. Russia
          10.2.7. Poland
          10.2.7. Rest of Europe
    10.3. Market Size (USD Million) Forecast for Europe 2021-2028

11. Asia Pacific Non-Alcoholic Steatohepatitis (Nash) Therapeutics And Diagnostics Market Analysis 2016-2020 and Forecast 2021-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Japan
          11.2.2. China
          11.2.3. India
          11.2.4. Australia and New Zealand
          11.2.5. ASEAN
          11.2.6. Rest of Asia Pacific
    11.3. Market Size (USD Million) Forecast for Asia Pacific 2021-2028  

12. Middle East and Africa Market Analysis 2016-2020 and Forecast 2021-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Saudi Arabia
          12.2.2. UAE
          12.2.3. South Africa
          12.2.4. Egypt
    12.3. Market Size (USD Million) Forecast for MEA 2021-2028

13. Market Share Analysis and Competitive Landscape   
    13.1. Global Landscape - Key Players, Revenue and Presence
    13.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    13.3. Global Emerging Companies
    13.4. North America - Market Share Analysis and Key Regional Players
    13.5. Europe - Market Share Analysis and Key Regional Players
    13.6. Asia Pacific - Market Share Analysis and Key Regional Players
    13.7. Global Key Player - Growth Matrix

14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    14.1. Abbvie Inc. (Allergan PLC.)
          14.1.1. Company Overview
          14.1.2. Product Portfolio
          14.1.3. SWOT Analysis
          14.1.4. Financial Overview
          14.1.5. Strategic Overview
    14.2. Novartis AG
          14.2.1. Company Overview
          14.2.2. Product Portfolio
          14.2.3. SWOT Analysis
          14.2.4. Financial Overview
          14.2.5. Strategic Overview 
    14.3. Quest Diagnostics
          14.3.1. Company Overview
          14.3.2. Product Portfolio
          14.3.3. SWOT Analysis
          14.3.4. Financial Overview
          14.3.5. Strategic Overview
    14.4. Exalenz Bioscience Ltd.
          14.4.1. Company Overview
          14.4.2. Product Portfolio
          14.4.3. SWOT Analysis
          14.4.4. Financial Overview
          14.4.5. Strategic Overview
    14.5. Intercept Pharmaceuticals Inc.
          14.5.1. Company Overview
          14.5.2. Product Portfolio
          14.5.3. SWOT Analysis
          14.5.4. Financial Overview
          14.5.5. Strategic Overview          
    14.6. Gilead Sciences Inc.
          14.6.1. Company Overview
          14.6.2. Product Portfolio
          14.6.3. SWOT Analysis
          14.6.4. Financial Overview
          14.6.5. Strategic Overview      
    14.7. Genfit SA
          14.7.1. Company Overview
          14.7.2. Product Portfolio
          14.7.3. SWOT Analysis
          14.7.4. Financial Overview
          14.7.5. Strategic Overview
    14.8. Novo Nordisk A/S
          14.8.1. Company Overview
          14.8.2. Product Portfolio
          14.8.3. SWOT Analysis
          14.8.4. Financial Overview
          14.8.5. Strategic Overview
    14.9. Zydus Cadila
          14.9.1. Company Overview
          14.9.2. Product Portfolio
          14.9.3. SWOT Analysis
          14.9.4. Financial Overview
          14.9.5. Strategic Overview
    14.10.Merck & Co.
          14.10.1. Company Overview
          14.10.2. Product Portfolio
          14.10.3. SWOT Analysis
          14.10.4. Financial Overview
          14.10.5. Strategic Overview
    14.11.OWL Metabolomics
          14.11.1. Company Overview
          14.11.2. Product Portfolio
          14.11.3. SWOT Analysis
          14.11.4. Financial Overview
          14.11.5. Strategic Overview

15. Pre and Post COVID-19 Impact
    15.1. Positive influence on the healthcare industry
    15.2. The financial disruption of the manufacturing sector
    15.3. Impact of COVID-19 on emerging companies
    15.4. Significant mandates in the healthcare regulations initiated by administrations
    15.5. The overall economic slowdown of the developing and developed nations

16. FutureWise SME Key Takeaway Points for Client

Tables

Figures